慢性炎症性脱髄性多発神経障害(CIDP)患者におけるヒト正常免疫グロブリン(IGIV)10%の静脈内投与を調査する研究
慢性炎症性脱髄性多発ニューロパシー(CIDP)患者におけるヒト正常免疫グロブリン(IGIV)10%の2つの異なる用量の静脈内投与の有効性と安全性を調査する二重盲検、無作為化、多施設共同研究
The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.
調査の概要
状態
詳細な説明
This is a Double Blind, Randomized study. All subjects will enter a wash-out phase of up to 12 weeks, or until functional deterioration, defined as an increase of ≥1 point (worsening) in the adjusted INCAT disability score, is demonstrated. Eligible subjects will then be randomized in a 1:2 ratio to receive either 0.5 g/kg or 1.0 g/kg KIg10 at 3-weekly intervals for 21 weeks. Subjects who relapse during randomized treatment due to functional deterioration, based on the INCAT score, will be rescued with 2.0 g/kg KIg10 at 3-weekly intervals for 21 weeks.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Anna Lotti Suffredini
- 電話番号:+39 338 6827568
- メール:a.lotti@kedrion.com
研究連絡先のバックアップ
- 名前:Esra Cinar-Jones
- 電話番号:+44 7551 563340
- メール:e.cinarjones@kedrion.com
研究場所
-
-
Connecticut
-
Stamford、Connecticut、アメリカ、06905
- 募集
- New England Institute for Clinical Research
-
主任研究者:
- Peter McAllister
-
-
Florida
-
Miami、Florida、アメリカ、33155
- 募集
- Quantix Research
-
主任研究者:
- Sergio Jaramillo
-
Pembroke Pines、Florida、アメリカ、33024
- 募集
- Best Choice Medical and Research Service
-
主任研究者:
- Vaniolky Losada Leon
-
Tampa、Florida、アメリカ、33613
- 募集
- USF Health - Morsani Center for Advanced Healthcare
-
主任研究者:
- Kathleen Murray
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- 募集
- Dartmouth-Hitchcock Medical Center
-
主任研究者:
- Victoria Lawson
-
-
Texas
-
El Paso、Texas、アメリカ、79912
- 募集
- Advanced Neurology Epilepsy and Sleep Center/ANESC Research
-
主任研究者:
- Aamr Herekar
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Male or female, aged ≥18 years.
-
Written informed consent and authorization to access personal health information obtained independently from participants indicating that they understand the purpose of, and procedures required for, the study and are willing to participate.
-
Documented diagnosis of CIDP consistent with the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria.
-
Current or documented history of significant disability, as defined by an overall INCAT disability score between 2 and 9. A score of 2 must be exclusively from the lower extremities.
-
Participants are currently dependent on treatment with immunoglobulins, corticosteroids, or standard of care treatments for CIDP.
-
Weakness of at least two limbs.
-
Participants should be clinically stable 12 weeks prior to screening date as defined by:
- without a worsening in INCAT score of ≥1 point, AND/OR without significant changes in clinical symptoms AND
- without significant dose changes or requiring additional treatments.
Exclusion Criteria:
-
Patients' incapable of giving informed consent.
-
Pure sensory and other CIDP variants.
-
Females who are pregnant, breastfeeding, unwilling to practice effective birth control methods as defined in Appendix C throughout the study, or planning a pregnancy during the study.
-
IG-experienced participants requiring an IGIV dosage of more than 1.4 g/kg/month OR SCIG pre-treated participants requiring a SCIG dosage of more than 1.6 g/kg/month.
-
Participants who have previously failed to respond to IGIV or SCIG.
-
On screening date, a body mass index (BMI) > 35 kg/m2 or an IGIV dose that puts the patient at risk of fluid overload.
-
CIDP and any neuropathy of other causes not consistent with the 2021 EAN/PNS criteria including:
- Hereditary demyelinating neuropathies, such as a hereditary sensory and motor neuropathy (HSMN) (Charcot-Marie-Tooth [CMT] disease), and hereditary sensory and autonomic neuropathies (HSANs).
- Neuropathies secondary to infections, disorders, or systemic diseases such as Borrelia burgdorferi infection (Lyme disease), diphtheria, systemic lupus erythematosus, POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome, osteosclerotic myeloma, diabetic and non-diabetic lumbosacral radiculoplexopathy or neuropathy, lymphoma, and amyloidosis.
- Multifocal motor neuropathy (MMN).
- Drug-, biologic-, chemotherapy-, or toxin-induced peripheral neuropathy. Peripheral neuropathy induced by vitamin B12 deficiency.
-
Immunoglobulin M (IgM) paraproteinemia, including IgM monoclonal gammopathy with increased titers of antibodies to myelin-associated glycoprotein.
-
Central demyelinating disorders (e.g, multiple sclerosis) or severe myopathy.
-
Any chronic or debilitating disease, or central nervous disorder that causes neurological symptoms or may interfere with assessment of CIDP or outcome measures (e.g., severe arthritis, stroke, Parkinson's disease, and diabetic peripheral neuropathy) [participants with clinically diagnosed diabetes mellitus, who have adequate glycemic control with Hemoglobin A1C (HbA1C) of <7.5% at screening, and who agree to maintain adequate glycemic control during the study are allowed].
-
Congestive heart failure (New York Heart Association (NYHA) Class III/IV), unstable angina, unstable cardiac arrhythmias, or uncontrolled hypertension [i.e., diastolic blood pressure >100 mmHg and/or systolic blood pressure >160 mmHg]. If a single measure exceeds this limit, a triple repeat measurement may be performed and the average of the three measurements used.
-
History of deep vein thrombosis or thromboembolic events (e.g, cerebrovascular accident, pulmonary embolism) in the past 12 months.
-
Condition(s) which could alter protein catabolism and/or IgG utilization (e.g, protein-losing enteropathies, nephrotic syndrome).
-
Known history of chronic kidney disease, or glomerular filtration rate (GFR) of <60 milliliter per minute per 1.73 square meter (mL/min/1.73m2) estimated based on an established chronic kidney disease epidemiology collaboration (CKD-EPI) equation at the time of screening.
-
Active malignancy requiring chemotherapy and/or radiotherapy, or history of malignancy with less than 2 years of complete remission prior to screening. Exceptions are adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment.
-
Hypersensitivity or adverse reactions (e.g, urticaria, breathing difficulty, severe hypotension, or anaphylaxis) to human blood products such as human IgG, albumin, or other blood components.
-
Known history of immunoglobulin A (IgA) deficiency.
-
Known history of autoimmune nodo-paranodopathies causing IG treatment resistance, including anti-neurofascin (NF) 186 antibodies and antibodies against paranodal proteins, such as NF155, contactin 1 (CNTN1), and contactin-associated protein 1 (CASPR1).
-
Abnormal laboratory values at screening:
- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5x upper limit of normal (ULN)
- Platelet count <100,000 cells/µL.
- Absolute neutrophil count (ANC) <1000 cells/µL.
- Clinically significant anemia or hemoglobin (Hgb) level of < 10.0 g/dL at screening.
-
Ongoing/active infection with hepatitis B virus (HBV), hepatitis C virus (HCV) or HIV Type 1/2 infection. Participants with chronic hepatitis B or hepatitis C infection currently on treatment may participate if they have undetectable viral load within 12 months of screening date.
-
Subjects who have received:
-
Within 2 months before wash-out phase:
- PE
- change in treatment of methotrexate, azathioprine, or mycophenolate
-
Within 3 months before wash-out phase: Efgartigimod alfa (Vyvgart)
-
Within 5 months before wash-out phase: cyclophosphamide, interferon, tumor necrosis factor-alpha inhibitors, fingolimod, or any other immunosuppressive medications
-
Within 12 months before wash-out phase: rituximab or alemtuzumab
-
-
Participants who have received a hematopoietic stem cell transplant.
-
Participants on corticosteroids for the treatment of CIDP after being fully washed out. Participants on maintenance doses of corticosteroid may be allowed, if treatment is for conditions unrelated to CIDP (doses usually below 20 mg/day prednisone or equivalent and where the dosage is unlikely to be tapered during the duration of the trial may be allowed for indications other than CIDP).
-
Any disorder or condition that in the investigator's judgment may impede the participant's participation in the study, pose increased risk to the participant, or confound the results of the study.
-
Participation in another clinical study involving an investigational medicinal product (IMP) or investigational device within 30 days prior to screening visit or within 5 half-lives of the IMP under investigation or is scheduled to participate in another clinical study involving an IMP or investigational device during the intended course of this study.
-
History of acquired or inherited thrombophilic disorders. These will include the specific types of acquired or inherited thrombophilic disorders that could put participants at risk of developing thrombotic events. Examples include, but are not restricted to:
-
Hereditary thrombophilia, examples include
- Factor V Leiden mutation.
- Prothrombin 20210A mutation.
- Protein C deficiency.
- Protein S deficiency.
- Antithrombin deficiency.
-
Acquired thrombophilias, examples include:
- Antiphospholipid antibody syndrome.
- Activated protein C Resistance acquired.
- Homocysteinemia.
-
-
Previous participation in this clinical study, except for participants who withdrew consent during the washout phase, prior to randomization.
-
Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:1.0 g/kg dose group for 24 weeks
This group will receive, initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion followed by 1.0 g/kg of IV KIg10 every 3 weeks. |
Kedrion intravenous immunoglobulin (IVIg) 10%
他の名前:
|
|
実験的:0.5 g/kg dose group for 24 weeks
This group will receive, Initial loading dose of 2.0 g/kg of Intravenous (IV) KIg10 (Immunoglobulin) infusion will be given followed by 0.5 g/kg of IV KIg10 every 3 weeks. |
Kedrion intravenous immunoglobulin (IVIg) 10%
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Efficacy of 1.0 g/kg KIg10 in the treatment of adult subjects with active CIDP
時間枠:From Baseline upto 24 weeks of treatment
|
The proportion of responders in the 1.0 g/kg KIg10 arm, at week 24 relative to Randomization Baseline week 0, based on the adjusted INCAT disability score. A responder is defined as having a ≥1 point decrease (improvement) in the adjusted INCAT score at week 24 relative to adjusted INCAT score at randomization baseline. |
From Baseline upto 24 weeks of treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Efficacy of 0.5 g/kg KIg10 in the treatment of adult subjects with active CIDP
時間枠:From Baseline upto 24 weeks of treatment
|
The proportion of responders in the 0.5 g/kg KIg10 arm at week 24 relative to randomization baseline, based on the adjusted INCAT disability score. A responder is defined as having a ≥1 point decrease (improvement) in the adjusted INCAT score at week 24 relative to adjusted INCAT score at randomization baseline. |
From Baseline upto 24 weeks of treatment
|
|
Proportion of responders (Week 24 vs Baseline) in both dose groups
時間枠:From Baseline upto 24 weeks of treatment
|
Proportion of responders in both dose groups based on Grip Strength and I-RODs |
From Baseline upto 24 weeks of treatment
|
|
Proportion of responders in rescued subjects
時間枠:End of Treatment vs onset of rescue treatment
|
Proportion of responders in rescued subjects based on grip strength, I-RODS scores, adjusted INCAT disability score |
End of Treatment vs onset of rescue treatment
|
|
Improvers based on the MRC-sumscore
時間枠:From Baseline upto 24 weeks of treatment
|
Improvers by a change of 4 points in both dose groups (week 24 versus baseline) based on MRC-sumscore |
From Baseline upto 24 weeks of treatment
|
|
Mean Change in MRC-sumscore
時間枠:From Baseline upto 24 weeks of treatment
|
Mean change in MRC-sumscore for both dose groups at week 24 vs baseline |
From Baseline upto 24 weeks of treatment
|
|
Mean Change in MRC-sumscore for rescued subjects
時間枠:End of Treatment vs onset of rescue treatment
|
Mean change in MRC-sumscore for rescued subjects from End of Treatment versus onset of rescue treatment |
End of Treatment vs onset of rescue treatment
|
|
Disease Related QoL (CAPPRI) for each dose level
時間枠:From Baseline upto 24 weeks of treatment
|
For each dose level the Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) will be analysed for disease related QoL |
From Baseline upto 24 weeks of treatment
|
|
Mean change in I-RODS
時間枠:From Baseline upto 24 weeks of treatment
|
For each dose level, mean change from randomization baseline (visit 2, week 0) to end of study (visit 10, week 24) in Inflammatory-Rasch-built Overall Disability Scale (I- RODS) score |
From Baseline upto 24 weeks of treatment
|
|
Mean change in I-RODS for rescued subjects
時間枠:End of Treatment vs onset of rescue treatment
|
Mean change to the end of treatment assessments prior to onset of rescue treatment, in Inflammatory-Rasch-built Overall Disability Scale (I- RODS) score for rescued subjects |
End of Treatment vs onset of rescue treatment
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of adverse events
時間枠:From Baseline upto 25 weeks
|
Assess Safety and Tolerability of KIg10 |
From Baseline upto 25 weeks
|
|
The proportion of patients experiencing at least one adverse event.
時間枠:From Baseline upto 25 weeks
|
Assess Safety and Tolerability of KIg10 |
From Baseline upto 25 weeks
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Lakshmi Deshpande、Kedrion S.p.A.
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- KB071
- KB071 (その他の識別子:Kedrion S.p.A)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Publishing of data and IPD that underlie results in the publication will be determined at study completion to comply with ICJME minimum requirements.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。